Geoffrey Porges
Stock Analyst at SVB Leerink
(1.33)
# 3,575
Out of 5,030 analysts
122
Total ratings
42.86%
Success rate
-6.75%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Geoffrey Porges
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PFE Pfizer | Maintains: Market Perform | $52 → $56 | $24.51 | +128.48% | 10 | Dec 15, 2021 | |
| RCUS Arcus Biosciences | Maintains: Outperform | $68 → $100 | $16.47 | +507.16% | 8 | Nov 18, 2021 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $798 → $850 | $578.05 | +47.05% | 16 | Nov 5, 2021 | |
| HALO Halozyme Therapeutics | Maintains: Outperform | $50 → $48 | $67.03 | -28.39% | 2 | Nov 3, 2021 | |
| AMGN Amgen | Maintains: Market Perform | $234 → $216 | $298.81 | -27.71% | 12 | Nov 3, 2021 | |
| ABBV AbbVie | Maintains: Outperform | $142 → $135 | $229.57 | -41.19% | 16 | Nov 1, 2021 | |
| ROIV Roivant Sciences | Initiates: Outperform | $11 | $17.26 | -36.27% | 1 | Nov 1, 2021 | |
| GILD Gilead Sciences | Maintains: Outperform | $77 → $75 | $122.81 | -38.93% | 14 | Oct 29, 2021 | |
| SNY Sanofi | Upgrades: Outperform | n/a | $50.62 | - | 2 | Sep 27, 2021 | |
| TBPH Theravance Biopharma | Maintains: Outperform | $29 → $10 | $14.26 | -29.87% | 9 | Sep 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $875 → $750 | $10.38 | +7,125.43% | 8 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $170 → $175 | $416.81 | -58.01% | 9 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $96 → $84 | $29.45 | +185.23% | 3 | May 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $43.91 | - | 1 | Mar 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $33 | $3.41 | +867.74% | 1 | Nov 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $61 | $7.81 | +681.05% | 2 | Nov 28, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $143.00 | - | 8 | Mar 16, 2017 |
Pfizer
Dec 15, 2021
Maintains: Market Perform
Price Target: $52 → $56
Current: $24.51
Upside: +128.48%
Arcus Biosciences
Nov 18, 2021
Maintains: Outperform
Price Target: $68 → $100
Current: $16.47
Upside: +507.16%
Regeneron Pharmaceuticals
Nov 5, 2021
Maintains: Outperform
Price Target: $798 → $850
Current: $578.05
Upside: +47.05%
Halozyme Therapeutics
Nov 3, 2021
Maintains: Outperform
Price Target: $50 → $48
Current: $67.03
Upside: -28.39%
Amgen
Nov 3, 2021
Maintains: Market Perform
Price Target: $234 → $216
Current: $298.81
Upside: -27.71%
AbbVie
Nov 1, 2021
Maintains: Outperform
Price Target: $142 → $135
Current: $229.57
Upside: -41.19%
Roivant Sciences
Nov 1, 2021
Initiates: Outperform
Price Target: $11
Current: $17.26
Upside: -36.27%
Gilead Sciences
Oct 29, 2021
Maintains: Outperform
Price Target: $77 → $75
Current: $122.81
Upside: -38.93%
Sanofi
Sep 27, 2021
Upgrades: Outperform
Price Target: n/a
Current: $50.62
Upside: -
Theravance Biopharma
Sep 16, 2021
Maintains: Outperform
Price Target: $29 → $10
Current: $14.26
Upside: -29.87%
Aug 10, 2021
Maintains: Outperform
Price Target: $875 → $750
Current: $10.38
Upside: +7,125.43%
Jul 30, 2021
Maintains: Underperform
Price Target: $170 → $175
Current: $416.81
Upside: -58.01%
May 10, 2021
Maintains: Market Perform
Price Target: $96 → $84
Current: $29.45
Upside: +185.23%
Mar 23, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $43.91
Upside: -
Nov 11, 2020
Initiates: Outperform
Price Target: $33
Current: $3.41
Upside: +867.74%
Nov 28, 2018
Initiates: Outperform
Price Target: $61
Current: $7.81
Upside: +681.05%
Mar 16, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $143.00
Upside: -